VCYT Stock Overview
Operates as a diagnostics company in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Veracyte, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.73 |
52 Week High | US$30.52 |
52 Week Low | US$18.61 |
Beta | 1.7 |
11 Month Change | 9.28% |
3 Month Change | 4.65% |
1 Year Change | -10.34% |
33 Year Change | -44.94% |
5 Year Change | -21.59% |
Change since IPO | 71.55% |
Recent News & Updates
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Recent updates
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Veracyte: Not A Healthy Diagnosis
May 12Shareholder Returns
VCYT | US Biotechs | US Market | |
---|---|---|---|
7D | 6.2% | 2.1% | -0.5% |
1Y | -10.3% | 12.0% | 24.2% |
Return vs Industry: VCYT underperformed the US Biotechs industry which returned 12% over the past year.
Return vs Market: VCYT underperformed the US Market which returned 24.2% over the past year.
Price Volatility
VCYT volatility | |
---|---|
VCYT Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VCYT has not had significant price volatility in the past 3 months.
Volatility Over Time: VCYT's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 815 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test.
Veracyte, Inc. Fundamentals Summary
VCYT fundamental statistics | |
---|---|
Market cap | US$1.75b |
Earnings (TTM) | -US$68.18m |
Revenue (TTM) | US$375.47m |
4.6x
P/S Ratio-25.5x
P/E RatioIs VCYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VCYT income statement (TTM) | |
---|---|
Revenue | US$375.47m |
Cost of Revenue | US$121.33m |
Gross Profit | US$254.14m |
Other Expenses | US$322.32m |
Earnings | -US$68.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.89 |
Gross Margin | 67.69% |
Net Profit Margin | -18.16% |
Debt/Equity Ratio | 0% |
How did VCYT perform over the long term?
See historical performance and comparison